• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    May 28, 2024 - FDA Approves First Interchangeable Biosimilar for Two Rare Diseases

    5/28/24 6:08:21 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AMGN alert in real time by email
    For Immediate Release:
    May 28, 2024

    Today, the U.S. Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the following treatment indications, which are also currently approved for Soliris:

    • the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis; and 
    • the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy.

    “Many rare conditions are life-threatening, and many do not have treatments,” said Sarah Yim, director of the Office of Therapeutic Biologics and Biosimilars in the FDA’s Center for Drug Evaluation and Research. “The FDA is committed to help facilitate the development of safe and effective interchangeable biosimilar treatments that can expand access for individuals with rare diseases whose current treatment options are limited.” 

    A disease is considered rare if it affects fewer than 200,000 people in the U.S. The conditions PNH and aHUS are rare diseases characterized by the breakdown of red blood cells. PNH results in anemia (low red blood cells), thrombosis (blood clots), pancytopenia (low counts of red blood cells, white blood cells, and platelets) and dark urine, while aHUS results in anemia, thrombocytopenia (low platelets) and kidney failure. 

    Bkemv is a monoclonal antibody that binds to the complement C5 protein and inhibits activation of the complement system, a part of the body’s immune system. This binding prevents the breakdown of red blood cells in the bloodstream (intravascular hemolysis) in patients with PNH and aHUS. 

    Bkemv, like Soliris, has a Boxed Warning that states that eculizumab products increase the risk of serious and life-threatening meningococcal infections caused by Neisseria meningitidis, the bacteria that causes meningitis and other potentially severe infections. Patients should have completed meningococcal vaccination before starting Bkemv or Soliris, be monitored for early signs and symptoms of meningococcal infections and undergo further evaluation immediately if signs of infection develop.

    As an interchangeable biosimilar, Bkemv is highly similar with no clinically meaningful differences to Soliris. Bkemv has the same safety warnings and is expected to have the same adverse reactions as Soliris. The most frequently reported adverse reactions in the PNH randomized trial for Soliris (≥10% overall and greater than placebo) are headache, nasopharyngitis (common cold), back pain and nausea. The most frequently reported adverse reactions in aHUS single arm prospective trials for Soliris (≥20%) are headache, diarrhea, hypertension, upper respiratory infection, abdominal pain, vomiting, nasopharyngitis, anemia, cough, swelling of lower legs or hands, nausea, urinary tract infections and fever. 

    Bkemv is available only through a restricted program called the Bkemv Risk Evaluation and Mitigation Strategy (REMS). A REMS is a drug safety program that the FDA can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks.

    Bkemv is the 53rd approved biosimilar in the U.S. The FDA has approved 13 of these as interchangeable biosimilars. 

    An interchangeable biosimilar is a biosimilar that has been shown to meet other requirements under the law and may be substituted for the reference product without consulting the prescriber. The substitution may occur at the pharmacy, subject to state pharmacy laws which vary by state, a practice commonly called “pharmacy-level substitution” — similar to generic drug substitution for brand name drugs. All biological products are approved only after meeting the FDA’s rigorous approval standards. This means health care providers and patients can expect the same safety and effectiveness from both a biosimilar and an interchangeable biosimilar, just as they would for a reference product.

    The approval of biosimilar and interchangeable biosimilar products furthers the FDA’s longstanding commitment to support a competitive marketplace for biological products and increase patient access to more affordable treatment options. 

    The FDA granted the approval of Bkemv to Amgen Inc.

    Related Information

    Related Information
    • Link to prescribing information for Bkemv
    • Biosimilar Resources for Health Care Providers and Patients
    • Biologic and Biosimilar Fact Sheet
    • FDA’s Purple Book: Database of Licensed Biological Products

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.


    Inquiries

    Media:
    Cherie Duvall-Jones
    301-357-0607
    Consumer:
    888-INFO-FDA

     
    Get the next $AMGN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AMGN

    DatePrice TargetRatingAnalyst
    5/20/2025$288.00Neutral
    Guggenheim
    4/22/2025$305.00Neutral
    Cantor Fitzgerald
    12/10/2024$256.00Underperform
    BofA Securities
    11/15/2024Peer Perform
    Wolfe Research
    11/14/2024$335.00Neutral
    Citigroup
    10/17/2024$380.00Outperform
    Bernstein
    10/14/2024$320.00 → $333.00Buy → Hold
    Truist
    9/27/2024$405.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $AMGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for REPATHA issued to AMGEN INC

      Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

      11/21/24 12:43:07 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for PAVBLU issued to AMGEN INC

      Submission status for AMGEN INC's drug PAVBLU (ORIG-1) with active ingredient AFLIBERCEPT has changed to 'Approval' on 08/23/2024. Application Category: BLA, Application Number: 761298, Application Classification:

      8/26/24 5:53:38 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for REPATHA issued to AMGEN INC

      Submission status for AMGEN INC's drug REPATHA (SUPPL-43) with active ingredient EVOLOCUMAB has changed to 'Approval' on 08/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

      8/21/24 12:12:47 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    SEC Filings

    See more
    • SEC Form 11-K filed by Amgen Inc.

      11-K - AMGEN INC (0000318154) (Filer)

      6/12/25 4:46:22 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 11-K filed by Amgen Inc.

      11-K - AMGEN INC (0000318154) (Filer)

      6/12/25 4:42:09 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Amgen Inc.

      10-Q - AMGEN INC (0000318154) (Filer)

      5/1/25 6:54:46 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim resumed coverage on Amgen with a new price target

      Guggenheim resumed coverage of Amgen with a rating of Neutral and set a new price target of $288.00

      5/20/25 8:11:08 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald resumed coverage on Amgen with a new price target

      Cantor Fitzgerald resumed coverage of Amgen with a rating of Neutral and set a new price target of $305.00

      4/22/25 7:29:10 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BofA Securities resumed coverage on Amgen with a new price target

      BofA Securities resumed coverage of Amgen with a rating of Underperform and set a new price target of $256.00

      12/10/24 8:12:28 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Amgen Inc converted options into 33,603,948 shares and bought $29,999,985 worth of shares (1,764,705 units at $17.00)

      4 - AMGEN INC (0000318154) (Reporting)

      9/19/23 7:52:07 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Business Development Khosla Rachna sold $434,520 worth of shares (1,500 units at $289.68), decreasing direct ownership by 16% to 8,162 units (SEC Form 4)

      4 - AMGEN INC (0000318154) (Issuer)

      6/6/25 7:49:22 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Miles Amy E was granted 809 shares, increasing direct ownership by 20% to 4,842 units (SEC Form 4)

      4 - AMGEN INC (0000318154) (Issuer)

      5/28/25 9:07:13 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Kullman Ellen Jamison was granted 809 shares, increasing direct ownership by 6% to 13,467 units (SEC Form 4)

      4 - AMGEN INC (0000318154) (Issuer)

      5/28/25 9:06:19 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER

      At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone THOUSAND OAKS, Calif., June 30, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis.  Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS as compared to placebo plus chemotherapy in people living with unresectable locally advanced or metastatic gastric or gastroesophageal j

      6/30/25 9:00:00 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AMGEN'S PHASE 2 MARITIDE DATA TO BE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS

      MariTide is the First Monthly or Less Frequently Dosed Peptide-Antibody Conjugate Being Investigated for the Treatment of Obesity and Type 2 Diabetes  New Repatha® Data Provide Insight Into the Benefits of Lipid Lowering Therapy in People With Type 1 Diabetes Amgen to Host Investor Webcast on MariTide Data on June 23 at 4:30 p.m. CDT  THOUSAND OAKS, Calif., June 18, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study for MariTide (maridebart cafraglutide, formerly AMG 133) in patients living with obesity, with and without Type 2 diabetes, will be presented along with new data from the Phase 3 FOURIER study of Repatha® (evolocumab) in cardio

      6/18/25 9:00:00 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AMGEN AND FOOTBALL LEGEND BARRY SANDERS HIGHLIGHT DANGERS OF BAD CHOLESTEROL IN NEW DOCUMENTARY

      The Making of a Heart Attack Educates Viewers About High LDL-C—a Major, but Modifiable, Risk Factor for Heart Attack and Stroke THOUSAND OAKS, Calif., June 13, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the launch of The Making of a Heart Attack, a documentary that sheds light on the cardiovascular disease crisis in the United States, where every 40 seconds someone has a heart attack or stroke.1 Experience the full interactive Multichannel News Release here: https://www.multivu.com/amgen/9340551-en-amgen-barry-sanders-highlight-dangers-bad-cholesterol-new-documentary The Making of a Heart Attack features renowned former football running back, Barry Sanders, who reveals he expe

      6/13/25 9:00:00 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    Leadership Updates

    Live Leadership Updates

    See more
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components
    • Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer

      Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer Arun Balakumaran M.D., Ph.D, appointed Chief Medical Officer of Replay to support the Company's genomic medicine and engineered NK cell therapy pipelineFormer Chief Medical Officer of allogeneic CAR-T cell company Allogene Therapeutics and seasoned industry immuno-oncology, and cell and gene therapy expert Dr. Balakumaran also appointed CMO of Syena, Replay's engineered NK cell therapy product company pioneering first-in-class engineered T-cell Receptor Natural Killer cell (TCR-NK) therapy San Diego, California and London, UK, May 18, 2023 – Replay, a genome writing company reprogramming biology by writing and deliver

      5/18/23 8:00:00 AM ET
      $ALLO
      $AMGN
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • AMGEN APPOINTS MICHAEL V. DRAKE TO BOARD OF DIRECTORS

      THOUSAND OAKS, Calif., Aug. 3, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the appointment of Michael V. Drake, M.D., to its Board of Directors, effective immediately.  Dr. Drake will also serve as a member of the Board's Corporate Responsibility and Compliance Committee and its Governance and Nominating Committee.  Following the appointment of Dr. Drake, the Board will be composed of 13 directors, 12 of whom are independent. Dr. Drake is president of the University of California, a system of 10 campuses, five medical centers and three nationally affiliated labs that serves more than 280,000 students and employs 230,000 faculty and staff. "Michael is an accomplished physician an

      8/3/22 4:05:00 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    Financials

    Live finance-specific insights

    See more
    • AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER

      At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone THOUSAND OAKS, Calif., June 30, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis.  Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS as compared to placebo plus chemotherapy in people living with unresectable locally advanced or metastatic gastric or gastroesophageal j

      6/30/25 9:00:00 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AMGEN'S PHASE 2 MARITIDE DATA TO BE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS

      MariTide is the First Monthly or Less Frequently Dosed Peptide-Antibody Conjugate Being Investigated for the Treatment of Obesity and Type 2 Diabetes  New Repatha® Data Provide Insight Into the Benefits of Lipid Lowering Therapy in People With Type 1 Diabetes Amgen to Host Investor Webcast on MariTide Data on June 23 at 4:30 p.m. CDT  THOUSAND OAKS, Calif., June 18, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study for MariTide (maridebart cafraglutide, formerly AMG 133) in patients living with obesity, with and without Type 2 diabetes, will be presented along with new data from the Phase 3 FOURIER study of Repatha® (evolocumab) in cardio

      6/18/25 9:00:00 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AMGEN AND FOOTBALL LEGEND BARRY SANDERS HIGHLIGHT DANGERS OF BAD CHOLESTEROL IN NEW DOCUMENTARY

      The Making of a Heart Attack Educates Viewers About High LDL-C—a Major, but Modifiable, Risk Factor for Heart Attack and Stroke THOUSAND OAKS, Calif., June 13, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the launch of The Making of a Heart Attack, a documentary that sheds light on the cardiovascular disease crisis in the United States, where every 40 seconds someone has a heart attack or stroke.1 Experience the full interactive Multichannel News Release here: https://www.multivu.com/amgen/9340551-en-amgen-barry-sanders-highlight-dangers-bad-cholesterol-new-documentary The Making of a Heart Attack features renowned former football running back, Barry Sanders, who reveals he expe

      6/13/25 9:00:00 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Amgen Inc. (Amendment)

      SC 13G/A - AMGEN INC (0000318154) (Subject)

      2/13/24 4:58:51 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Amgen Inc. (Amendment)

      SC 13G/A - AMGEN INC (0000318154) (Subject)

      1/30/24 11:35:57 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Amgen Inc.

      SC 13D - AMGEN INC (0000318154) (Filed by)

      9/27/23 7:30:51 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care